Plasminogen activator inhibitor 1 structure
P05121
PAI1_HUMAN
SERPINE1

Plasminogen activator inhibitor 1

Homo sapiensTaxon: 9606

3D-structureAlternative splicingDirect protein sequencingGlycoproteinProtease inhibitorProteomics identificationReference proteomeSecretedSerine protease inhibitorSignal
Longueur de Séquence

402

acides aminés

Poids Moléculaire

45.1 kDa

théorique

Structures Expérimentales

29

entrées PDB

Maladies Associées

1

enregistrées

Fonction

Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:17912461, PubMed:8481516, PubMed:9207454, PubMed:21925150). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084)

Localisation & Distribution

Spécificité Tissulaire

Expressed in endothelial cells (PubMed:2430793, PubMed:3097076). Found in plasma, platelets, and hepatoma and fibrosarcoma cells

Maladies Associées

Plasminogen activator inhibitor-1 deficiency

A hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen.

Séquence d'Acides Aminés

MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD

Format FASTA · 402 acides aminés · masse 45.1 kDa

Structures Expérimentales

29 entrées PDB
1A7C1B3K1C5G1DB21DVM1DVN1LJ51OC03CVM3EOX3PB13Q023Q033R4L3UT34AQH4G8O4G8R4IC05BRR5ZLZ6GWN6GWP6GWQ6I8S6ZRV7AQF7AQG9PAI

Modifications Post-Traductionnelles

  • Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond